KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Equity Income (2019 - 2025)

Historic Equity Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $18.9 million.

  • Royalty Pharma's Equity Income fell 6290.39% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.5 million, marking a year-over-year decrease of 17282.14%. This contributed to the annual value of $39.5 million for FY2024, which is 5461.39% down from last year.
  • Royalty Pharma's Equity Income amounted to $18.9 million in Q3 2025, which was down 6290.39% from -$30.6 million recorded in Q2 2025.
  • Royalty Pharma's Equity Income's 5-year high stood at $77.7 million during Q1 2024, with a 5-year trough of -$66.6 million in Q4 2021.
  • Over the past 5 years, Royalty Pharma's median Equity Income value was -$5.2 million (recorded in 2023), while the average stood at -$538894.7.
  • Its Equity Income has fluctuated over the past 5 years, first plummeted by 24440.78% in 2021, then skyrocketed by 107374.57% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Equity Income stood at -$66.6 million in 2021, then surged by 84.28% to -$10.5 million in 2022, then skyrocketed by 626.59% to $55.1 million in 2023, then crashed by 175.99% to -$41.9 million in 2024, then surged by 145.01% to $18.9 million in 2025.
  • Its Equity Income stands at $18.9 million for Q3 2025, versus -$30.6 million for Q2 2025 and -$45.9 million for Q1 2025.